[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 1953


Author Affiliations


AMA Arch Derm Syphilol. 1953;68(5):572-574. doi:10.1001/archderm.1953.01540110094014

The antihistaminic compound Diphenylpyraline (1-methyl-piperidyll-4 benzhydryl ether) has been reported to have marked in vitro antifungal activity against many of the common strains causing inflammatory changes in the human skin. Carson and Campbell1 reported that this drug showed marked activity in vitro against Trichophyton rubrum, Microsporum gypseum, Microsporum lanosum, Epidermophyton floccosum, and Candida albicans. Sokoloff2 reported clinical evaluation of this drug on 103 patients in New Jersey. Further clinical studies in the hot and humid climate of the Carolina coastal country were thought worth while. One hundred thirty-seven patients with various fungous infections of the skin as well as with a few miscellaneous dermatoses were treated.

One side-effect of the drug, a distinct antipruritic effect, was apparent in most of the cases and warranted trial in some miscellaneous dermatoses which are also reported here. Sensitization to the drug was noticeably absent, although some patients complained of burning of